Early-Stage cancer drug trial halted after just 3 patients

NCT ID NCT07159828

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times

Summary

This early-phase study tested a new drug called AXN-2510 in 3 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to find safe doses and understand side effects. The trial was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Carolina BioOncology

    Huntersville, North Carolina, 28078, United States

  • NEXT Houston

    Houston, Texas, 77054, United States

  • NEXT San Antonio

    San Antonio, Texas, 78229, United States

  • NEXT Virginia

    Fairfax, Virginia, 22031, United States

  • New Experimental Therapeutics (NEXT) Oncology - Houston

    Houston, Texas, 77054, United States

  • New Experimental Therapeutics of San Antonio - NEXT Oncology

    San Antonio, Texas, 78229, United States

  • Sarah Cannon Research Institute at Mary Crowley

    Dallas, Texas, 75251, United States

Conditions

Explore the condition pages connected to this study.